Viking Therapeutics, Inc.

NasdaqCM:VKTX Stok Raporu

Piyasa değeri: US$8.1b

Viking Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Viking Therapeutics's earnings have been declining at an average annual rate of -25.6%, while the Biotechs industry saw earnings growing at 19% annually.

Anahtar bilgiler

-25.6%

Kazanç büyüme oranı

-18.3%

EPS büyüme oranı

Biotechs Sektör Büyümesi17.0%
Gelir büyüme oranın/a
Özkaynak getirisi-10.9%
Net Marjn/a
Son Kazanç Güncellemesi30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09
Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

Gelir ve Gider Dağılımı

Viking Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

NasdaqCM:VKTX Gelir, gider ve kazançlar (USD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Sep 240-994391
30 Jun 240-973887
31 Mar 240-943777
31 Dec 230-863764
30 Sep 230-813259
30 Jun 230-742853
31 Mar 230-722253
31 Dec 220-691654
30 Sep 220-621548
30 Jun 220-591347
31 Mar 220-571246
31 Dec 210-551145
30 Sep 210-541044
30 Jun 210-501041
31 Mar 210-441035
31 Dec 200-391132
30 Sep 200-361129
30 Jun 200-321027
31 Mar 200-311027
31 Dec 190-26924
30 Sep 190-24922
30 Jun 190-24823
31 Mar 190-23820
31 Dec 180-22719
30 Sep 180-21717
30 Jun 180-20615
31 Mar 180-19613
31 Dec 170-21514
30 Sep 170-20513
30 Jun 170-18512
31 Mar 170-16511
31 Dec 160-1559
30 Sep 160-16510
30 Jun 160-17610
31 Mar 160-2169
31 Dec 150-2357
30 Sep 150-1744
30 Jun 150-1222
31 Mar 150-27122
31 Dec 140-22122
30 Sep 140-23122
30 Jun 140-23121
31 Mar 140000

Kaliteli Kazançlar: VKTX is currently unprofitable.

Büyüyen Kar Marjı: VKTX is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: VKTX is unprofitable, and losses have increased over the past 5 years at a rate of 25.6% per year.

Büyüme Hızlandırma: Unable to compare VKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: VKTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Özkaynak Getirisi

Yüksek ROE: VKTX has a negative Return on Equity (-10.88%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin